Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Revenue (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Revenue data on record, last reported at $6.6 million in Q4 2025.

  • For Q4 2025, Revenue rose 130.4% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $14.6 million, up 53.24%, while the annual FY2025 figure was $14.6 million, 53.24% up from the prior year.
  • Revenue reached $6.6 million in Q4 2025 per LCTX's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Revenue topped out at $6.6 million in Q4 2025 and bottomed at $391000.0 in Q1 2021.
  • Average Revenue over 5 years is $2.7 million, with a median of $2.4 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 1239.39% in 2022, then plummeted 58.44% in 2023.
  • A 5-year view of Revenue shows it stood at $2.3 million in 2021, then fell by 15.64% to $1.9 million in 2022, then grew by 6.79% to $2.0 million in 2023, then soared by 40.24% to $2.9 million in 2024, then skyrocketed by 130.4% to $6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $6.6 million in Q4 2025, $3.7 million in Q3 2025, and $2.8 million in Q2 2025.